KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $38.3 million.

  • Xenon Pharmaceuticals' Total Current Liabilities rose 2909.58% to $38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.3 million, marking a year-over-year increase of 2909.58%. This contributed to the annual value of $35.6 million for FY2024, which is 3049.54% up from last year.
  • Xenon Pharmaceuticals' Total Current Liabilities amounted to $38.3 million in Q3 2025, which was up 2909.58% from $33.0 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Total Current Liabilities high stood at $38.3 million for Q3 2025, and its period low was $8.0 million during Q1 2022.
  • Over the past 5 years, Xenon Pharmaceuticals' median Total Current Liabilities value was $22.7 million (recorded in 2022), while the average stood at $23.1 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Total Current Liabilities tumbled by 7631.69% in 2021, and later soared by 18177.15% in 2023.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Total Current Liabilities stood at $14.3 million in 2021, then skyrocketed by 58.51% to $22.7 million in 2022, then grew by 20.13% to $27.3 million in 2023, then skyrocketed by 30.5% to $35.6 million in 2024, then rose by 7.71% to $38.3 million in 2025.
  • Its last three reported values are $38.3 million in Q3 2025, $33.0 million for Q2 2025, and $32.0 million during Q1 2025.